Figure 2From: An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophreniaPositive and Negative Syndrome Scale (PANSS) total score over time (observed cases). Data are presented as mean (SD). Data are presented for all subjects to the 6- or 12-month end point. The RIS/RIS 6- and 12-month groups are mutually exclusiveBack to article page